Shares of Aeluma (ALMU) slid 10.3% to $14.31 on Thursday as traders cashed in gains from a multi-day surge that lifted the stock from $14.60 to above $16 in just three sessions. No new negative headline triggered the drop — this is a textbook profit-taking pullback in a thinly traded micro-cap, compounded by broader semiconductor sector weakness.
The Contract That Started the Party Is Tiny by Chip-Industry Standards
Aeluma secured more than $4 million in U.S. government contracts to scale its semiconductor platform for quantum and high-speed data communication. That sounds meaningful until you consider the context: Aeluma narrowed its full-year fiscal 2026 revenue guidance to just $4.2 million to $4.6 million. In other words, one contract cluster roughly equals an entire year of sales — a positive sign for backlog, but a reminder that the company generates less quarterly revenue than a busy restaurant. Q3 fiscal 2026 revenue came in at just $1.2 million with a GAAP net loss of $1.8 million, while cash stood at $37.8 million.
Government Money Keeps the Lights On, but Commercial Revenue Is Still Missing
Aeluma's current revenues are limited to government R&D contracts, with no commercial adoption or material revenue visibility yet. The company is targeting AI data centers, defense, and automotive markets, but risks include contract delays, supply chain disruptions in rare earth materials, and competition from larger peers like Lumentum or Coherent. Until a paying commercial customer appears, the stock trades on promise, not proof.
Insiders Have Been Selling Steadily Into Strength
In the past six months, insiders executed 61 trades — all sales, zero purchases — with major shareholder Mark Tompkins alone selling 980,845 shares for roughly $16.9 million.
CEO Jonathan Klamkin's sales were pre-planned under a Rule 10b5-1 trading plan , but the sheer volume of insider liquidation at a company with no profits warrants attention.
The Valuation Demands a Leap of Faith
Aeluma is positioned in high-growth areas like AI, defense, and quantum computing, with a market cap near $345 million. That is roughly 75 times its guided annual revenue. Analysts have lifted their price target to about $28.67 , but that thesis rests entirely on commercialization breakthroughs that remain unproven. Today's pullback is healthy mechanics; the real test is whether Aeluma can convert lab-stage contracts into production-scale revenue before its $37.8 million cash cushion runs thin.